<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>临床试验招募信息 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2021-01-07T07:39:28+08:00</updated>
  <subtitle>帮您更方便、更快捷的了解正在开展的临床试验招募信息！</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>【翰中PD-1招募11】抗PD-1 单克隆抗体HX008 治疗甲状腺未分化癌的单臂、开放、多中心 II 期临床研究</title>
    <updated>2021-01-07T07:00:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-07:/s/wDplF-CYLrD8QpnFdfK-9w</id>
    <link href="https://mp.weixin.qq.com/s/wDplF-CYLrD8QpnFdfK-9w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【君实PD-1招募34】特瑞普利单抗联合仑伐替尼对比仑伐替尼单药一线治疗晚期肝细胞癌前瞻性随机对照双盲多中心III期临床研究</title>
    <updated>2021-01-07T07:00:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-07:/s/FXGXyFcuTrrwFsF-OmxTwA</id>
    <link href="https://mp.weixin.qq.com/s/FXGXyFcuTrrwFsF-OmxTwA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【翰中PD-1招募10】抗PD-1单克隆抗体HX008联合贝伐珠单抗或仑伐替尼一线治疗晚期肝细胞癌的II期临床研究</title>
    <updated>2021-01-06T07:54:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-06:/s/Q-t3krbuGNi3HOVbCmYm9A</id>
    <link href="https://mp.weixin.qq.com/s/Q-t3krbuGNi3HOVbCmYm9A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【君实PD-1招募34】特瑞普利单抗联合仑伐替尼对比仑伐替尼单药一线治疗晚期肝细胞癌前瞻性随机对照双盲多中心III期临床研究</title>
    <updated>2021-01-06T07:54:28+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-06:/s/pT2gPlJSy1u5C7V_FtEKyg</id>
    <link href="https://mp.weixin.qq.com/s/pT2gPlJSy1u5C7V_FtEKyg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】APL-1202对比表柔比星膀胱灌注治疗对未经治疗的膀胱癌有效性和安全性的随机、开放、平行对照、多中心临床研究</title>
    <updated>2021-01-05T08:01:04+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-05:/s/0Ailwa4_SRDWE_F9cjAH4A</id>
    <link href="https://mp.weixin.qq.com/s/0Ailwa4_SRDWE_F9cjAH4A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【君实PD-1招募34】特瑞普利单抗联合仑伐替尼对比仑伐替尼单药一线治疗晚期肝细胞癌前瞻性随机对照双盲多中心III期临床研究</title>
    <updated>2021-01-05T08:01:04+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-05:/s/zBP62yd7MI4wQgiyWNwh6g</id>
    <link href="https://mp.weixin.qq.com/s/zBP62yd7MI4wQgiyWNwh6g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>肿瘤病人究竟能不能接种新冠疫苗？</title>
    <updated>2021-01-04T07:50:03+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-04:/s/gNUCXnk98tinP2b86omkmw</id>
    <link href="https://mp.weixin.qq.com/s/gNUCXnk98tinP2b86omkmw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【君实PD-1招募34】特瑞普利单抗联合仑伐替尼对比仑伐替尼单药一线治疗晚期肝细胞癌前瞻性随机对照双盲多中心III期临床研究</title>
    <updated>2021-01-04T07:50:03+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-04:/s/vAzGZ4U3eQW3yGtKymcElA</id>
    <link href="https://mp.weixin.qq.com/s/vAzGZ4U3eQW3yGtKymcElA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【罗氏PD-L1招募患者30】经肝动脉化疗栓塞术联合阿替利珠单抗加贝伐珠单抗用于未经治疗的肝细胞：一项III期、开放、随机研究</title>
    <updated>2021-01-03T09:53:45+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-03:/s/lvZzD5OFfIY9Yz3NMCfHig</id>
    <link href="https://mp.weixin.qq.com/s/lvZzD5OFfIY9Yz3NMCfHig" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【君实PD-1招募34】特瑞普利单抗联合仑伐替尼对比仑伐替尼单药一线治疗晚期肝细胞癌前瞻性随机对照双盲多中心III期临床研究</title>
    <updated>2021-01-03T09:53:45+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-03:/s/LKhIED8ngERS-go011xjAw</id>
    <link href="https://mp.weixin.qq.com/s/LKhIED8ngERS-go011xjAw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【默沙东PD-1招募30】比较帕博利珠单抗联合化疗对比安慰剂联合化疗一线治疗晚期和/或不可切除的胆道癌的III期试验</title>
    <updated>2020-12-31T08:08:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-31:/s/KD4SClTcGFQTISUyVdy7CQ</id>
    <link href="https://mp.weixin.qq.com/s/KD4SClTcGFQTISUyVdy7CQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【君实PD-1招募34】特瑞普利单抗联合仑伐替尼对比仑伐替尼单药一线治疗晚期肝细胞癌前瞻性随机对照双盲多中心III期临床研究</title>
    <updated>2020-12-31T08:08:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-31:/s/pgGt7XC4MR-ok2Ppr0ZCnQ</id>
    <link href="https://mp.weixin.qq.com/s/pgGt7XC4MR-ok2Ppr0ZCnQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【招募患者】MRG003治疗经一线或以上含标准治疗失败的EGFR阳性无法手术切除的局部晚期或转移性胆道腺癌的II期临床试验</title>
    <updated>2020-12-30T07:26:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-30:/s/8VDqMu9Pzjpp649Iq4jDlg</id>
    <link href="https://mp.weixin.qq.com/s/8VDqMu9Pzjpp649Iq4jDlg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【君实PD-1招募34】特瑞普利单抗联合仑伐替尼对比仑伐替尼单药一线治疗晚期肝细胞癌前瞻性随机对照双盲多中心III期临床研究</title>
    <updated>2020-12-30T07:26:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-30:/s/CYmbEe5SVYxkhg_gJIS6Bg</id>
    <link href="https://mp.weixin.qq.com/s/CYmbEe5SVYxkhg_gJIS6Bg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【翰中PD-1招募10】抗PD-1单克隆抗体HX008联合贝伐珠单抗或仑伐替尼一线治疗晚期肝细胞癌的II期临床研究</title>
    <updated>2020-12-29T07:25:57+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-29:/s/tjQUv1MJ8XuA0J5-L2EOfQ</id>
    <link href="https://mp.weixin.qq.com/s/tjQUv1MJ8XuA0J5-L2EOfQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【君实PD-1招募34】特瑞普利单抗联合仑伐替尼对比仑伐替尼单药一线治疗晚期肝细胞癌前瞻性随机对照双盲多中心III期临床研究</title>
    <updated>2020-12-29T07:25:57+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-29:/s/_pii2NwMoYfmEoRE6U64XQ</id>
    <link href="https://mp.weixin.qq.com/s/_pii2NwMoYfmEoRE6U64XQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>ASCO对肿瘤病人是否应该接种新冠疫苗的态度</title>
    <updated>2020-12-28T07:08:54+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-28:/s/T3DEO7cCbUbffAhG6Oa23w</id>
    <link href="https://mp.weixin.qq.com/s/T3DEO7cCbUbffAhG6Oa23w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【君实PD-1招募34】特瑞普利单抗联合仑伐替尼对比仑伐替尼单药一线治疗晚期肝细胞癌前瞻性随机对照双盲多中心III期临床研究</title>
    <updated>2020-12-28T07:08:54+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-28:/s/jx8V5OFoJpnOYqODp_dytg</id>
    <link href="https://mp.weixin.qq.com/s/jx8V5OFoJpnOYqODp_dytg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【罗氏PD-L1招募患者29】术后或消融术后高复发风险的肝细胞癌患者中比较阿替利珠单抗联合贝伐珠单抗作为辅助治疗与主动监测的研究</title>
    <updated>2020-12-27T11:00:52+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-27:/s/AgWrMH9eCPXxUJVRn_NkMg</id>
    <link href="https://mp.weixin.qq.com/s/AgWrMH9eCPXxUJVRn_NkMg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【君实PD-1招募34】特瑞普利单抗联合仑伐替尼对比仑伐替尼单药一线治疗晚期肝细胞癌前瞻性随机对照双盲多中心III期临床研究</title>
    <updated>2020-12-27T11:00:52+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-27:/s/g9KkwpJ1W9KN9JAa2toPOA</id>
    <link href="https://mp.weixin.qq.com/s/g9KkwpJ1W9KN9JAa2toPOA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>